Gotistobart Nearly Doubles Survival in Squamous NSCLC, Boosting BioNTech's Oncology Pipeline
BNTX sits 25% above its 52-week low of $79.52.
Summary
BioNTech and OncoC4 presented updated data from the non-pivotal stage 1 of the PRESERVE-003 Phase 3 trial showing gotistobart nearly doubled median overall survival versus docetaxel in previously treated squamous NSCLC: 18.5 months vs 10.0 months (HR 0.56, p=0.0295). This is the first median OS data from the trial and was presented at IASLC 2026 WCLC. The safety profile was manageable, with Grade ≥3 TRAEs in 44.4% vs 48.8% for docetaxel. The pivotal stage 2 is ongoing at over 160 sites. This positive data strengthens BioNTech's oncology pipeline at a time when the company has faced setbacks, including the termination of its colorectal cancer trial in August and a guidance cut. The survival benefit, if confirmed in the pivotal portion, could transform the standard of care in a setting with limited options.
At the time of this announcement, BNTX was trading at $99.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.3B. The 52-week trading range was $79.52 to $124.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.